| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jia Luo | |
| Julie N. Graff | |||
| P2860 | cites work | Development of a second-generation antiandrogen for treatment of advanced prostate cancer | Q24605577 |
| Global cancer statistics, 2012 | Q27860501 | ||
| Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. | Q53585661 | ||
| Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. | Q54710973 | ||
| Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer | Q58068307 | ||
| Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial | Q87195630 | ||
| Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials | Q89251440 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
| Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Q30277291 | ||
| EQ-5D: a measure of health status from the EuroQol Group | Q34086093 | ||
| Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness | Q34150812 | ||
| Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials | Q34315605 | ||
| Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). | Q34354355 | ||
| Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 | ||
| Enzalutamide: Development from bench to bedside | Q34468131 | ||
| U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer | Q35915730 | ||
| Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial | Q36914459 | ||
| Characterising the castration-resistant prostate cancer population: a systematic review | Q37945316 | ||
| Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity | Q38179119 | ||
| Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. | Q38399938 | ||
| Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. | Q40090587 | ||
| Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study | Q40100457 | ||
| Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). | Q40239582 | ||
| Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial | Q40950557 | ||
| Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomi | Q41049323 | ||
| A controlled trial of leuprolide with and without flutamide in prostatic carcinoma | Q41261975 | ||
| Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial | Q42058811 | ||
| Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial | Q43491856 | ||
| Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. | Q44018378 | ||
| Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy | Q44830519 | ||
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 | Q45957143 | ||
| Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial | Q48161067 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 217-224 | |
| P577 | publication date | 2016-11-29 | |
| P1433 | published in | Research and reports in urology | Q27725046 |
| P1476 | title | Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives | |
| P478 | volume | 8 |
| Q52677958 | Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. |
| Q52608122 | Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. |
Search more.